Compounding Regulation Bill In Senate May Actually Encourage More Activity, Groups Argue
This article was originally published in The Pink Sheet Daily
Executive Summary
Some stakeholders worry that increased oversight of compounding may incentivize an expansion of the sector over traditional FDA-controlled manufacturing, but a compounding trade group thinks some provisions restrict prescriber ability to customize medications.